Shigella outer membrane protein PSSP-1 is broadly protective against Shigella infection

Clinical and Vaccine Immunology

Volumn 22, Issue 4, 2015, Pages 381-388

  Kim, Jae Ouk ^a   Rho, Semi ^a   Kim, Su Hee ^a   Kim, Heejoo ^a   Song, Hyo Jin ^a   Kim, Eun Jin ^a   Kim, Ryang Yeo ^a   Kim, Eun Hye ^a   Sinha, Anuradha ^b   Dey, Ayan ^a   Yang, Jae Seung ^a   Song, Man Ki ^a   Nandy, Ranjan Kumar ^b   Czerkinsky, Cecil ^a,c   Kim, Dong Wook ^a,d  

^a International Vaccine Institute   (South Korea)

^b NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES   (India)

^c INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^d Hanyang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; BACTERIAL TOXIN; CHOLERA TOXIN; GAMMA INTERFERON; HEAT LABILE TOXIN; INTERLEUKIN 17; OUTER MEMBRANE PROTEIN; PAN SHIGELLA SURFACE PROTEIN 1; SHIGELLA VACCINE; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS PROTECTION; CYTOKINE PRODUCTION; EXPERIMENTAL INFECTION; FEMALE; HUMAN; MOUSE; MOUSE MODEL; MUCOSAL IMMUNITY; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; SEROTYPE; SHIGELLA; SHIGELLA BOYDII; SHIGELLA DYSENTERIAE; SHIGELLA FLEXNERI; SHIGELLA SONNEI; SHIGELLOSIS; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; DYSENTERY, BACILLARY; HETEROLOGOUS IMMUNITY; IMMUNOLOGY; INFANT; INTRADERMAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; PNEUMONIA, BACTERIAL; PRESCHOOL CHILD; SECRETION (PROCESS);

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; CHILD, PRESCHOOL; CROSS PROTECTION; DYSENTERY, BACILLARY; FEMALE; HUMANS; IMMUNITY, HETEROLOGOUS; INFANT; INJECTIONS, INTRADERMAL; INTERFERON-GAMMA; INTERLEUKIN-17; MICE; MICE, INBRED BALB C; PNEUMONIA, BACTERIAL; SHIGELLA; SHIGELLA VACCINES;

EID: 84925381519     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00661-14     Document Type: Article

References (39)

1. Livio S, Strockbine NA, Panchalingam S, Tennant SM, Barry EM, Marohn ME, Antonio M, Hossain A, Mandomando I, Ochieng JB, Oundo JO, Qureshi S, Ramamurthy T, Tamboura B, Adegbola RA, Hossain MJ, Saha D, Sen S, Faruque AS, Alonso PL, Breiman RF, Zaidi AK, Sur D, Sow SO, Berkeley LY, O'Reilly CE, Mintz ED, Biswas K, Cohen D, Farag TH, Nasrin D, Wu Y, Blackwelder WC, Kotloff KL, Nataro JP, Levine MM. 2014. Shigella isolates from the Global Enteric Multicenter Study inform vaccine development. Clin Infect Dis 59:933-941. http://dx.doi.org/10.1093/cid/ciu468.
2. Niyogi SK. 2005. Shigellosis. J Microbiol 43:133-143.
3. World Health Organization. 2005. Shigellosis: disease burden, epidemiology and case management. Wkly Epidemiol Rec 80:94-99.
4. von Seidlein L, Kim DR, Ali M, Lee H, Wang X, Thiem VD, Canh do G, Chaicumpa W, Agtini MD, Hossain A, Bhutta ZA, Mason C, Sethabutr O, Talukder K, Nair GB, Deen JL, Kotloff K, Clemens J. 2006. A multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology. PLoS Med 3:e353. http://dx.doi.org/10.1371/journal.pmed.0030353.
5. Fukuda I, Suzuki T, Munakata H, Hayashi N, Katayama E, Yoshikawa M, Sasakawa C. 1995. Cleavage of Shigella surface protein VirG occurs at a specific site, but the secretion is not essential for intracellular spreading. J Bacteriol 177:1719-1726.
6. Robbins JR, Monack D, McCallum SJ, Vegas A, Pham E, Goldberg MB, Theriot JA. 2001. The making of a gradient: IcsA (VirG) polarity in Shigella flexneri. Mol Microbiol 41:861-872.
7. Goldberg MB, Barzu O, Parsot C, Sansonetti PJ. 1993. Unipolar localization and ATPase activity of IcsA, a Shigella flexneri protein involved in intracellular movement. J Bacteriol 175:2189-2196.
8. Lett MC, Sasakawa C, Okada N, Sakai T, Makino S, Yamada M, Komatsu K, Yoshikawa M. 1989. virG, a plasmid-coded virulence gene of Shigella flexneri: identification of the virG protein and determination of the complete coding sequence. J Bacteriol 171:353-359.
9. Wing HJ, Yan AW, Goldman SR, Goldberg MB. 2004. Regulation of IcsP, the outer membrane protease of the Shigella actin tail assembly protein IcsA, by virulence plasmid regulators VirF and VirB. J Bacteriol 186: 699-705. http://dx.doi.org/10.1128/JB.186.3.699-705.2004.
10. Lycke N, Holmgren J. 1988. Mucosal immune response to cholera toxin: cellular basis of memory and adjuvant action. Monogr Allergy 24:274-281.
11. Norton EB, Lawson LB, Freytag LC, Clements JD. 2011. Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant. Clin Vaccine Immunol 18:546-551. http://dx.doi.org/10.1128/CVI.00538-10.
12. Wei J, Goldberg MB, Burland V, Venkatesan MM, Deng W, Fournier G, Mayhew GF, Plunkett G, III, Rose DJ, Darling A, Mau B, Perna NT, Payne SM, Runyen-Janecky LJ, Zhou S, Schwartz DC, Blattner FR. 2003. Complete genome sequence and comparative genomics of Shigella flexneri serotype 2a strain 2457T. Infect Immun 71:2775-2786. http://dx.doi.org/10.1128/IAI.71.5.2775-2786.2003.
13. Onodera NT, Ryu J, Durbic T, Nislow C, Archibald JM, Rohde JR. 2012. Genome sequence of Shigella flexneri serotype 5a strain M90T Sm. J Bacteriol 194:3022. http://dx.doi.org/10.1128/JB.00393-12.
14. Romanowska E, Katzenellenbogen E, Lugowski C, Gamian A, Bogulska M. 1978. Immunochemical characteristics of Shigella sonnei and serotype 6 Shigella flexneri lipopolysaccharides and enterobacterial common antigen. Arch Immunol Ther Exp (Warsz) 26:249-254.
15. Dacosta B, Ryter A, Mounier J, Sansonetti P. 1990. Immunodetection of lipopolysaccharide in macrophages during the processing of non invasive Shigella dysenteriae. Biol Cell 69:171-178. http://dx.doi.org/10.1016/0248-4900(90)90343-2.
16. Coster TS, Hoge CW, VanDeVerg LL, Hartman AB, Oaks EV, Venkatesan MM, Cohen D, Robin G, Fontaine-Thompson A, Sansonetti PJ, Hale TL. 1999. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect Immun 67:3437-3443.
17. Lan R, Stevenson G, Reeves PR. 2003. Comparison of two major forms of the Shigella virulence plasmid pINV: positive selection is a major force driving the divergence. Infect Immun 71:6298-6306. http://dx.doi.org/10.1128/IAI.71.11.6298-6306.2003.
18. Shim BS, Choi YK, Yun CH, Lee EG, Jeon YS, Park SM, Cheon IS, Joo DH, Cho CH, Song MS, Seo SU, Byun YH, Park HJ, Poo H, Seong BL, Kim JO, Nguyen HH, Stadler K, Kim DW, Hong KJ, Czerkinsky C, Song MK. 2011. Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza. PLoS One 6:e27953. http://dx.doi.org/10.1371/journal.pone.0027953.
19. Kim DW, Lenzen G, Page AL, Legrain P, Sansonetti PJ, Parsot C. 2005. The Shigella flexneri effector OspG interferes with innate immune responses by targeting ubiquitin-conjugating enzymes. Proc Natl Acad Sci U S A 102:14046-14051. http://dx.doi.org/10.1073/pnas.0504466102.
20. Demarre G, Guerout AM, Matsumoto-Mashimo C, Rowe-Magnus DA, Marliere P, Mazel D. 2005. A new family of mobilizable suicide plasmids based on broad host range R388 plasmid (IncW) and RP4 plasmid (IncPα) conjugative machineries and their cognate Escherichia coli host strains. Res Microbiol 156:245-255. http://dx.doi.org/10.1016/j.resmic.2004.09.007.
21. Noh Y, Shim BS, Cheon IS, Rho S, Kim HJ, Choi Y, Kang CY, Chang J, Song MK, Kim JO. 2013. Neonatal immunization with respiratory syncytial virus glycoprotein fragment induces protective immunity in the presence of maternal antibodies in mice. Viral Immunol 26:268-276. http://dx.doi.org/10.1089/vim.2012.0087.
22. Saletti G, Cuburu N, Yang JS, Dey A, Czerkinsky C. 2013. Enzyme-linked immunospot assays for direct ex vivo measurement of vaccine-induced human humoral immune responses in blood. Nat Protoc 8:1073-1087. http://dx.doi.org/10.1038/nprot.2013.058.
23. Venkatesan MM, Buysse JM, Kopecko DJ. 1988. Characterization of invasion plasmid antigen genes (ipaBCD) from Shigella flexneri. Proc Natl Acad Sci U S A 85:9317-9321. http://dx.doi.org/10.1073/pnas.85.23.9317.
24. Martinez-Becerra FJ, Kissmann JM, Diaz-McNair J, Choudhari SP, Quick AM, Mellado-Sanchez G, Clements JD, Pasetti MF, Picking WL. 2012. Broadly protective Shigella vaccine based on type III secretion apparatus proteins. Infect Immun 80:1222-1231. http://dx.doi.org/10.1128/IAI.06174-11.
25. Shere KD, Sallustio S, Manessis A, D'Aversa TG, Goldberg MB. 1997. Disruption of IcsP, the major Shigella protease that cleaves IcsA, accelerates actin-based motility. Mol Microbiol 25:451-462. http://dx.doi.org/10.1046/j.1365-2958.1997.4681827.x.
26. Voino-Yasenetsky MV, Voino-Yasenetskaya MK. 1962. Experimental pneumonia caused by bacteria of the Shigella group. Acta Morphol Acad Sci Hung 11:439-454.
27. Summerton NA, Welch RW, Bondoc L, Yang HH, Pleune B, Ramachandran N, Harris AM, Bland D, Jackson WJ, Park S, Clements JD, Nabors GS. 2010. Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin. Vaccine 28:1404-1411. http://dx.doi.org/10.1016/j.vaccine.2009.10.147.
28. Sellge G, Magalhaes JG, Konradt C, Fritz JH, Salgado-Pabon W, Eberl G, Bandeira A, Di Santo JP, Sansonetti PJ, Phalipon A. 2010. Th17 cells are the dominant T cell subtype primed by Shigella flexneri mediating protective immunity. J Immunol 184:2076-2085. http://dx.doi.org/10.4049/jimmunol.0900978.
29. Raqib R, Gustafsson A, Andersson J, Bakhiet M. 1997. A systemic downregulation of gamma interferon production is associated with acute shigellosis. Infect Immun 65:5338-5341.
30. Berlin C, Berg EL, Briskin MJ, Andrew DP, Kilshaw PJ, Holzmann B, Weissman IL, Hamann A, Butcher EC. 1993. α4β7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 74:185-195. http://dx.doi.org/10.1016/0092-8674(93)90305-A.
31. Eriksson K, Quiding-Jarbrink M, Osek J, Nordstrom I, Hjulstrom M, Holmgren J, Czerkinsky C. 1999. Anatomic segmentation of the intestinal immune response in nonhuman primates: differential distribution of B cells after oral and rectal immunizations to sites defined by their source of vascularization. Infect Immun 67:6210-6212.
32. Venkatesan MM, Buysse JM, Kopecko DJ. 1989. Use of Shigella flexneri ipaC and ipaH gene sequences for the general identification of Shigella spp. and enteroinvasive Escherichia coli. J Clin Microbiol 27:2687-2691.
33. Barry EM, Pasetti MF, Sztein MB, Fasano A, Kotloff KL, Levine MM. 2013. Progress and pitfalls in Shigella vaccine research. Nat Rev Gastroenterol Hepatol 10:245-255. http://dx.doi.org/10.1038/nrgastro.2013.12.
34. Jann K, Goldemann G, Weisgerber C, Wolf-Ullisch C, Kanegasaki S. 1982. Biosynthesis of the O9 antigen of Escherichia coli: initial reaction and overall mechanism. Eur J Biochem 127:157-164. http://dx.doi.org/10.1111/j.1432-1033.1982.tb06850.x.
35. Raetz CR, Whitfield C. 2002. Lipopolysaccharide endotoxins. Annu Rev Biochem 71:635-700. http://dx.doi.org/10.1146/annurev.biochem.71.110601.135414.
36. Van den Bosch L, Manning PA, Morona R. 1997. Regulation of O-antigen chain length is required for Shigella flexneri virulence. Mol Microbiol 23:765-775. http://dx.doi.org/10.1046/j.1365-2958.1997.2541625.x.
37. Tran EN, Doyle MT, Morona R. 2013. LPS unmasking of Shigella flexneri reveals preferential localisation of tagged outer membrane protease IcsP to septa and new poles. PLoS One 8:e70508. http://dx.doi.org/10.1371/journal.pone.0070508.
38. Carter JA, Jimenez JC, Zaldivar M, Alvarez SA, Marolda CL, Valvano MA, Contreras I. 2009. The cellular level of O-antigen polymerase Wzy determines chain length regulation by WzzB and WzzpHS-2 in Shigella flexneri 2a. Microbiology 155:3260-3269. http://dx.doi.org/10.1099/mic.0.028944-0.
39. Shim D-H, Suzuki T, Chang S-Y, Park S-M, Sansonetti PJ, Sasakawa C, Kweon M-N. 2007. New animal model of shigellosis in the guinea pig: its usefulness for protective efficacy studies. J Immunol 178:2476-2482. http://dx.doi.org/10.4049/jimmunol.178.4.2476.